Wainman Paul R 4

What Happened

• Paul R. Wainman, a director of ImmuCell Corp. (ICCC), received a grant of 11,933 derivative awards (stock options) on April 15, 2026. The Form 4 reports an acquisition price of $0.00, meaning no cash was paid by the insider for the award. The filing notes the options were granted to compensate directors for board services.

Key Details

• Transaction date: 2026-04-15; Form 4 filed 2026-04-16 (timely filing).
• Award: 11,933 options reported as acquired at $0.00 (derivative instrument).
• Vesting schedule (footnote): 3,977 options vest on April 15, 2027; 3,977 on April 15, 2028; 3,979 on April 15, 2029.
• Shares owned after the transaction: not specified in the filing.
• Remarks: Grant expressly provided as director compensation (routine equity award).

Context

• This was a grant of options (a compensation award), not a stock purchase or sale. Options do not represent immediately tradable stock until vested and exercised; the filing does not indicate any exercise or sale. Director awards are common for board compensation and do not by themselves signal insider buying or selling intentions.